Pfizer Inc vs Verisign, Inc. — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Verisign, Inc. trades at $262.86 (market cap $24.22B). The key difference: Pfizer Inc is far larger — about 5.9× Verisign, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | VRSN | |
|---|---|---|
Market Cap | $142.14B | $24.22B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $28.56 | $310.00 |
52-Week Low | $23.29 | $211.49 |
Enterprise Value | $192.80B | $25.46B |
Dividend Yield | 6.9% | 1.22% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →